223 related articles for article (PubMed ID: 9872607)
1. Parenteral inotropic support for advanced congestive heart failure.
Leier CV; Binkley PF
Prog Cardiovasc Dis; 1998; 41(3):207-24. PubMed ID: 9872607
[TBL] [Abstract][Full Text] [Related]
2. Outpatient parenteral inotropic therapy for advanced heart failure.
Young JB; Moen EK
J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
[TBL] [Abstract][Full Text] [Related]
3. General overview and update of positive inotropic therapy.
Leier CV
Am J Med; 1986 Oct; 81(4C):40-5. PubMed ID: 2946223
[TBL] [Abstract][Full Text] [Related]
4. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure.
Siostrzonek P; Koreny M; Delle-Karth G; Haumer M; Koller-Strametz J; Heinz G
Acta Anaesthesiol Scand; 2000 Apr; 44(4):403-9. PubMed ID: 10757572
[TBL] [Abstract][Full Text] [Related]
5. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
[TBL] [Abstract][Full Text] [Related]
7. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
[TBL] [Abstract][Full Text] [Related]
8. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
Bayram M; De Luca L; Massie MB; Gheorghiade M
Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
[TBL] [Abstract][Full Text] [Related]
9. Continuous Intravenous Milrinone Therapy in Pediatric Outpatients.
Curley M; Liebers J; Maynard R
J Infus Nurs; 2017; 40(2):92-96. PubMed ID: 28248808
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
11. Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Chatterjee K; De Marco T
Med Clin North Am; 2003 Mar; 87(2):391-418. PubMed ID: 12693731
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Karlsberg RP; DeWood MA; DeMaria AN; Berk MR; Lasher KP
Clin Cardiol; 1996 Jan; 19(1):21-30. PubMed ID: 8903534
[TBL] [Abstract][Full Text] [Related]
13. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F
Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466
[TBL] [Abstract][Full Text] [Related]
14. Effects of milrinone on systemic hemodynamics and regional circulations in dogs with congestive heart failure: comparison with dobutamine.
Liang CS; Thomas A; Imai N; Stone CK; Kawashima S; Hood WB
J Cardiovasc Pharmacol; 1987 Nov; 10(5):509-16. PubMed ID: 2447398
[TBL] [Abstract][Full Text] [Related]
15. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
[TBL] [Abstract][Full Text] [Related]
16. [New inotropic agents in the treatment of congestive heart failure].
Freitas M
Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
[TBL] [Abstract][Full Text] [Related]
17. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
[TBL] [Abstract][Full Text] [Related]
18. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function.
Capomolla S; Pozzoli M; Opasich C; Febo O; Riccardi G; Salvucci F; Maestri R; Sisti M; Cobelli F; Tavazzi L
Am Heart J; 1997 Dec; 134(6):1089-98. PubMed ID: 9424070
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
20. Myocardial and vascular actions of milrinone.
Colucci WS
Eur Heart J; 1989 Aug; 10 Suppl C():32-8. PubMed ID: 2680495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
